Department of Biochemistry and Microbiology, Nelson Mandela University, Port Elizabeth 6031, South Africa.
Enzyme Science Programme (ESP), Department of Biochemistry and Microbiology, Rhodes University, Makhanda 6140, South Africa.
Biomed Pharmacother. 2024 Oct;179:117357. doi: 10.1016/j.biopha.2024.117357. Epub 2024 Sep 3.
Obesity is a chronic noncommunicable disease characterized by excessive body fat that can have negative health consequences. Obesity is a complex disease caused by a combination of genetic, environmental, and lifestyle factors. It is characterized by a discrepancy between caloric intake and expenditure. Obesity increases the risk of acquiring major chronic diseases, including heart disease, stroke, cancer, and Type 2 diabetes mellitus (T2DM). Currently, the inhibition of pancreatic lipases (PL) is a promising pharmacological therapy for obesity and weight management. In this study, the inhibition of pancreatic lipase by Cannabis sativa (C. sativa) plant extract and cannabinoids was investigated.
The inhibitory effect was assessed using p-nitrophenyl butyrate (pNPB), and the results were obtained by calculating the percentage relative activity and assessed using one-way analysis of variance (ANOVA). Kinetic studies and spectroscopy techniques were used to evaluate the mode of inhibition. Diet-induced; and diabetic rat models were studied to evaluate the direct effects of C. sativa extract on PL activity.
Kinetic analyses showed that the plant extracts inhibited pancreatic lipase, with tetrahydrocannabinol (THC) and cannabinol (CBN) being the potential cause of the inhibition noted for the C. sativa plant extract. CBN and THC inhibited the pancreatic lipase activity in a competitive manner, with the lowest residual enzyme activity of 52 % observed at a 10 μg/mL concentration of CBN and 39 % inhibition at a 25 μg/mL concentration of THC. Circular dichroism (CD) spectroscopy revealed that the inhibitors caused a change in the enzyme's secondary structure. At low concentrations, THC showed potential for synergistic inhibition with orlistat. C.sativa treatment in an in vivo rat model confirmed its inhibitory effects on pancreatic lipase activity.
The findings in this study provided insight into the use of cannabinoids as pancreatic lipase inhibitors and the possibility of using these compounds to develop new pharmacological treatments for obesity.
肥胖是一种慢性非传染性疾病,其特征是体脂肪过多,会对健康产生负面影响。肥胖是一种由遗传、环境和生活方式因素共同作用引起的复杂疾病。其特征是热量摄入与消耗之间存在差异。肥胖会增加罹患主要慢性疾病的风险,包括心脏病、中风、癌症和 2 型糖尿病(T2DM)。目前,抑制胰腺脂肪酶(PL)是肥胖和体重管理的一种有前途的药物治疗方法。在这项研究中,研究了大麻(C. sativa)植物提取物和大麻素对胰腺脂肪酶的抑制作用。
使用对硝基苯丁酸(pNPB)评估抑制作用,通过计算相对活性百分比获得结果,并使用单向方差分析(ANOVA)进行评估。动力学研究和光谱技术用于评估抑制模式。研究了饮食诱导的肥胖和糖尿病大鼠模型,以评估 C. sativa 提取物对 PL 活性的直接影响。
动力学分析表明,植物提取物抑制了胰腺脂肪酶,四氢大麻酚(THC)和大麻醇(CBN)是 C. sativa 植物提取物抑制作用的潜在原因。CBN 和 THC 以竞争性方式抑制胰腺脂肪酶活性,在 10 μg/mL CBN 浓度下观察到最低残留酶活性为 52%,在 25 μg/mL THC 浓度下抑制率为 39%。圆二色性(CD)光谱表明,抑制剂导致酶的二级结构发生变化。在低浓度下,THC 显示出与奥利司他协同抑制的潜力。在体内大鼠模型中,C.sativa 治疗证实了其对胰腺脂肪酶活性的抑制作用。
本研究结果提供了关于大麻素作为胰腺脂肪酶抑制剂的使用的见解,并为开发肥胖的新药物治疗方法提供了使用这些化合物的可能性。